XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Information

11. Segment Information

The Company has identified two operating and reportable segments: Cell Engineering and Biosecurity. The following table presents summary results of the Company’s reportable segments for the periods indicated (in thousands):

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2023

 

 

2022 (as adjusted)*

 

 

2023

 

 

2022 (as adjusted)*

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Cell Engineering

$

45,283

 

 

$

44,242

 

 

$

79,379

 

 

$

65,730

 

Biosecurity

 

35,285

 

 

 

100,376

 

 

 

81,891

 

 

 

247,293

 

Total revenue

 

80,568

 

 

 

144,618

 

 

 

161,270

 

 

 

313,023

 

Segment cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

Biosecurity

 

18,096

 

 

 

63,911

 

 

 

40,471

 

 

 

149,343

 

Segment research and development expense:

 

 

 

 

 

 

 

 

 

 

 

Cell Engineering

 

86,083

 

 

 

63,948

 

 

 

184,605

 

 

 

112,359

 

Biosecurity

 

528

 

 

 

443

 

 

 

1,095

 

 

 

960

 

Total segment research and development expense

 

86,611

 

 

 

64,391

 

 

 

185,700

 

 

 

113,319

 

Segment general and administrative expense:

 

 

 

 

 

 

 

 

 

 

 

Cell Engineering

 

50,907

 

 

 

36,601

 

 

 

112,599

 

 

 

63,294

 

Biosecurity

 

16,699

 

 

 

12,409

 

 

 

30,655

 

 

 

25,644

 

Total segment general and administrative expense

 

67,606

 

 

 

49,010

 

 

 

143,254

 

 

 

88,938

 

Segment operating (loss) income:

 

 

 

 

 

 

 

 

 

 

 

Cell Engineering

 

(91,707

)

 

 

(56,307

)

 

 

(217,825

)

 

 

(109,923

)

Biosecurity

 

(38

)

 

 

23,613

 

 

 

9,670

 

 

 

71,346

 

Total segment operating loss

 

(91,745

)

 

 

(32,694

)

 

 

(208,155

)

 

 

(38,577

)

Operating expenses not allocated to segments:

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation (1)

 

62,477

 

 

 

607,270

 

 

 

137,677

 

 

 

1,266,305

 

Depreciation and amortization

 

17,652

 

 

 

9,028

 

 

 

36,610

 

 

 

17,968

 

Asset impairment

 

9,001

 

 

 

 

 

 

9,001

 

 

 

 

Change in fair value of contingent consideration liability

 

3,276

 

 

 

(1,213

)

 

 

8,453

 

 

 

300

 

Loss from operations

$

(184,151

)

 

$

(647,779

)

 

$

(399,896

)

 

$

(1,323,150

)

* As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

(1) Includes $1.0 million and $0.8 million in employer payroll taxes for the three months ended June 30, 2023 and 2022, respectively, and $3.2 million and $7.0 million in employer payroll taxes for the six months ended June 30, 2023 and 2022, respectively.